Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2024-07-01 DOI:10.1016/j.cllc.2024.04.003

Amit A. Kulkarni , Cassandra Hennessy , Grace Wilson , Vidhyalakshmi Ramesh , Clara Hwang , Joy Awosika , Ziad Bakouny , Hina Khan , Diana Vilar-Compte , Rana McKay , Chinmay Jani , Lisa Weissmann , Elizabeth Griffiths , Gerald Batist , Nathaniel Bouganim , Blanche Mavromatis , Babar Bashir , Ryan H. Nguyen , Jonathan W. Riess , Matthew Puc , Narjust Florez

{"title":"Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis","authors":"Amit A. Kulkarni , Cassandra Hennessy , Grace Wilson , Vidhyalakshmi Ramesh , Clara Hwang , Joy Awosika , Ziad Bakouny , Hina Khan , Diana Vilar-Compte , Rana McKay , Chinmay Jani , Lisa Weissmann , Elizabeth Griffiths , Gerald Batist , Nathaniel Bouganim , Blanche Mavromatis , Babar Bashir , Ryan H. Nguyen , Jonathan W. Riess , Matthew Puc , Narjust Florez","doi":"10.1016/j.cllc.2024.04.003","DOIUrl":null,"url":null,"abstract":"<div><ul><li>•Patients with thoracic cancers and COVID-19 have high mortality and morbidity.</li><li>•Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited.</li><li>•We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19).</li><li>•As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity.</li><li>•None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality.</li><li>•Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.</li></ul></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424000445","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

•
Patients with thoracic cancers and COVID-19 have high mortality and morbidity.
•
Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited.
•
We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19).
•
As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity.
•
None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality.
•
Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.

查看原文本刊更多论文

简要报告：抗癌治疗对胸腺癌患者 COVID-19 治疗结果的影响：CCC19 登记分析

-我们分析了胸部癌症患者和COVID-19患者（N=927）的临床数据，系统评估了COVID-19和癌症联盟（CCC19）近期抗癌疗法对COVID-19临床结果的影响。-与免疫疗法或靶向疗法不同，近期（COVID-19确诊前3个月）接受的细胞毒性化疗与COVID-19的严重程度显著相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.